Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial

Muhammad I Husain, Imran B Chaudhry, Ameer B Khoso, Mohammad Omair Husain, Raza R Rahman, Munir M Hamirani, John Hodsoll, Andre F Carvalho, Nusrat Husain, Allan H Young, Muhammad I Husain, Imran B Chaudhry, Ameer B Khoso, Mohammad Omair Husain, Raza R Rahman, Munir M Hamirani, John Hodsoll, Andre F Carvalho, Nusrat Husain, Allan H Young

Abstract

Background: A third of patients diagnosed with major depressive disorder (MDD) experience treatment-resistant depression (TRD). Relatively few pharmacological agents have established efficacy for TRD. Therefore, the evaluation of novel treatments for TRD is a pressing priority. Statins are pleiotropic agents and preclinical studies as well as preliminary clinical trials have suggested that these drugs may have antidepressant properties.AimsTo report on a protocol for a 12-week, randomised, double-blind, placebo-controlled trial of add-on treatment with simvastatin for patients meeting DSM-5 criteria for MDD who have failed to respond to at least two adequate trials with approved antidepressants. The trial has been registered with Clinicaltrials.gov in (ClinicalTrials.gov identifier: NCT03435744).

Method: After screening and randomisation to the two parallel arms of the trial, 75 patients will receive simvastatin and 75 patients will receive placebo as adjuncts to treatment as usual. The primary outcome is change in Montgomery-Åsberg Depression Rating Scale scores from baseline to week 12 and secondary outcomes include changes in scores on the 24-item Hamilton Rating Scale for Depression, the Clinical Global Impression scale, the 7-item Generalized Anxiety Disorder scale and change in body mass index from baseline to week 12. Assessments will take place at screening, baseline, and weeks 2, 4, 8 and 12. Checklists for adverse effects will be undertaken at each visit. Simvastatin (20 mg) will be given once daily. Other secondary outcomes include C-reactive protein and plasma lipids measured at baseline and week 12.

Results: This trial will assess simvastatin's efficacy and tolerability as an add-on treatment option for patients with TRD and provide insights into its putative mechanisms of action.

Conclusions: As the first trial investigating the use of simvastatin as an augmentation strategy in patients with TRD, if the results indicate that adjuvant simvastatin is efficacious in reducing depressive symptoms, it will deliver immediate clinical benefit.Declaration of interestI.B.C. and N.H. have given lectures and advice to Eli Lilly, Bristol Myers Squibb, Lundbeck, Astra Zeneca and Janssen pharmaceuticals for which they or their employing institution have been reimbursed. R.R. and M.M.H. have received educational grants and support for academic meetings from Pfizer, Roche, Novartis and Nabiqasim. A.H.Y. has been commissioned to provide lectures and advice to all major pharmaceutical companies with drugs used in affective and related disorders. A.H.Y. has undertaken investigator-initiated studies from Astra Zeneca, Eli Lilly, Lundbeck and Wyeth. None of the companies have a financial interest in this research.

Keywords: Depressive disorders; low and middle income countries; neuroimmunology; novel CNS drugs; randomized controlled trial.

Figures

Fig. 1
Fig. 1
Flow chart of randomised controlled trial.

References

    1. World Health Organisation. Depression and Other Common Mental Disorders Global Health Estimates. WHO, 2017.
    1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
    1. Carvalho AF, Berk M, Hyphantis TN, McIntyre RS. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 2014; 83: 70–88.
    1. Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol 2015; 13: 636–55.
    1. Ludka FK, Constantino LC, Kuminek G, Binder LB, Zomkowski AD, Cunha MP, et al. Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice. Pharmacol Biochem Behav 2014; 122: 253–60.
    1. Köhler O, Gasse C, Petersen L, Ingstrup KG, Nierenberg AA, Mors O, et al. The effect of concomitant treatment with SSRIs and statins: a population-based study. Am J Psychiatry 2016; 173: 807–15.
    1. Parsaik AK, Singh B, Murad MH, Singh K, Mascarenhas SS, Williams MD, et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62–7.
    1. Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a metaanalysis of randomized, double-blind, placebo-controlled trials. J Affect Disord 2016; 200: 235–42.
    1. Köhler-Forsberg O, Gasse C, Berk M, Østergaard SD. Do statins have antidepressant effects? CNS Drugs 2017; 31: 335–43.
    1. McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci 2014; 15: 20607–37.
    1. Herbet M, Izdebska M, Piątkowska-Chmiel I, Poleszak E, Jagiełło-Wójtowicz E. Estimation of oxidative stress parameters in rats after simultaneous administration of rosuvastatin with antidepressants. Pharmacol Rep 2016; 68: 172–6.
    1. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46–62.
    1. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017; 135: 373–87.
    1. Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 2018; 55: 4195–206.
    1. Parekh A, Smeeth D, Milner Y, Thuret S. The role of lipid biomarkers in major depression. Healthcare 2017; 5: 5.
    1. Lamers F, Milaneschi Y, de Jonge P, Giltay EJ, Penninx BWJH. Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychol Med 2018; 48: 1102–10.
    1. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2010; 13: 15–30.
    1. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005; 312: 786–93.
    1. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U, et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2006; 316: 1146–52.
    1. Ma K, Zhang H, Baloch Z. Pathogenetic and therapeutic applications of tumor necrosis factor-α (TNF-α) in major depressive disorder: a systematic review. Int J Mol Sci 2016; 17: 733–53.
    1. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and metaregression. J Affect Disord 2012; 139: 230–9.
    1. First MB, Williams JBW, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). American Psychiatric Association, 2015.
    1. Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour N, et al. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J Psychopharmacol 2015; 29: 575–81.
    1. Montgomery SA, Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
    1. Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017; 17: 58.
    1. Husain MI, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol 2017; 31: 1166–75.
    1. Hamilton M. Rating depressive patients. J Clin Psychiatry 1980; 41: 21–4.
    1. Joint Formulary Committee. British National Formulary. BMJ Group and Pharmaceutical Press, 2017.
    1. Taylor D, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines (13th edn). CRC Press, 2018.
    1. Carmody T, Rush AJ, Bernstein I, et al. The Montgomery Äsberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601–11.
    1. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601–11.
    1. Busner J, Targum SD. The Clinical Global Impressions scale. Psychiatry (Edgmont) 2007; 4: 28–37.
    1. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–7.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care 1986; 24: 67–74.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.
    1. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378–82.
    1. Muthén LK, Muthén BO. Mplus User's Guide (7th edn). Muthén & Muthén, 1998. –2012.
    1. Fritz MS, MacKinnon DP. Required sample size to detect the mediated effect. Psychol Sci 2007; 18: 233–9.
    1. Wium-Andersen MK, Orsted DD, Nielsen SF, et al. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013; 70: 176–84.
    1. Benati D, Ferro M, Savino MT, Ulivieri C, Schiavo E, Nuccitelli A, et al. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J Leukoc Biol 2009; 87: 433–42.
    1. Loike JD. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 2004; 24: 2051–6.
    1. Muniz-Junqueira MI, Karnib SR, de Paula-Coelho VN, Junqueira LF. Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. Int Immunopharmacol 2006; 6: 53–60.
    1. Salman H, Bergman M, Djaldetti M, Bessler H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother 2008; 62: 41–5.
    1. Tanaka N, Abe-Dohmae S, Iwamoto N, Fitzgerald ML, Yokoyama S. HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. Atherosclerosis 2011; 217: 407–14.
    1. Djaldetti M, Salman H, Bergman M, Bessler H. Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Exp Mol Pathol 2006; 80: 160–4.
    1. Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011; 23: 307–18.
    1. Setiawan E, Attwells S, Wilson AA, Mizrahi R, Rusjan PM, Miler L, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry 2018; 5: 339–47.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren